These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 11017151

  • 1. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.
    Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L.
    Nat Med; 2000 Oct; 6(10):1176-82. PubMed ID: 11017151
    [Abstract] [Full Text] [Related]

  • 2. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
    Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R.
    Nat Med; 2000 Oct; 6(10):1167-75. PubMed ID: 11017150
    [Abstract] [Full Text] [Related]

  • 3. Transdermal application of myelin peptides in multiple sclerosis treatment.
    Walczak A, Siger M, Ciach A, Szczepanik M, Selmaj K.
    JAMA Neurol; 2013 Sep 01; 70(9):1105-9. PubMed ID: 23817921
    [Abstract] [Full Text] [Related]

  • 4. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
    Deraos G, Rodi M, Kalbacher H, Chatzantoni K, Karagiannis F, Synodinos L, Plotas P, Papalois A, Dimisianos N, Papathanasopoulos P, Gatos D, Tselios T, Apostolopoulos V, Mouzaki A, Matsoukas J.
    Eur J Med Chem; 2015 Aug 28; 101():13-23. PubMed ID: 26112377
    [Abstract] [Full Text] [Related]

  • 5. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Aug 28; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients.
    Crowe PD, Qin Y, Conlon PJ, Antel JP.
    Ann Neurol; 2000 Nov 28; 48(5):758-65. PubMed ID: 11079539
    [Abstract] [Full Text] [Related]

  • 10. Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
    Chataway J, Martin K, Barrell K, Sharrack B, Stolt P, Wraith DC, ATX-MS1467 Study Group.
    Neurology; 2018 Mar 13; 90(11):e955-e962. PubMed ID: 29467307
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 13; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Specific immunotherapy: one size does not fit all.
    Genain CP, Zamvil SS.
    Nat Med; 2000 Oct 13; 6(10):1098-100. PubMed ID: 11017135
    [No Abstract] [Full Text] [Related]

  • 15. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA.
    J Clin Invest; 2000 Apr 13; 105(7):967-76. PubMed ID: 10749576
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
    Warren KG, Catz I, Ferenczi LZ, Krantz MJ.
    Eur J Neurol; 2006 Aug 13; 13(8):887-95. PubMed ID: 16879301
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.
    Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T, MAESTRO-01 Investigators.
    Neurology; 2011 Oct 18; 77(16):1551-60. PubMed ID: 21975206
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.